Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 2280-2282
10.1182/blood-2022-158404